UroGen Pharma (URGN) Insider Cynthia Butitta Buys 10,000 Shares
Cynthia Butitta purchased 8,000 shares of URGN on June 22, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Cynthia Butitta bought 10,000 shares of UroGen Pharma Ltd. ($URGN) on June 22, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $URGN is up 3.1% after 1 week, up 20.2% after 1 month and down 1.2% to date (from the $34.99 close on Jun 22, 2026).
URGN
UroGen Pharma Ltd.
Key Points
- Cynthia Butitta acquired 8,000 shares of URGN on June 22, 2026, with shares trading near $35.80 on Wednesday.
- RTW Investments holds 4,543,895 shares worth about $81.7 million; BlackRock increased its stake by 244,558 shares to 2,845,567 shares valued at $51.2 million.
- Analysts from HC Wainwright & Co. and Oppenheimer maintain a 'buy' rating on URGN, with price targets of $45 and $40, respectively.
Get $URGN trade alerts by text
We text you when insiders, Congress or big funds trade $URGN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated UroGen Pharma Ltd. alert may contain errors. Disclosures
Cynthia Butitta, an insider at URGN, purchased 8,000 shares on June 22, 2026. This transaction was not part of a pre-planned trading strategy and was reported with the transaction code 'A'. On Wednesday, URGN shares traded around $35.80.
Other Institutional Activity in URGN
RTW Investments, LP holds a significant stake in URGN with 4,543,895 shares worth approximately $81.7 million, maintaining its position without any change in shares. BlackRock, Inc. increased its holdings by 244,558 shares, bringing its total to 2,845,567 shares valued at $51.2 million, marking a 9.4% increase. Toronto Dominion Bank opened a new position with 2,616,714 shares, valued at $47.0 million. Morgan Stanley slightly reduced its stake by 2,863 shares to 2,560,038 shares, valued at $46.0 million. Kynam Capital Management, LP also opened a new position, acquiring 2,247,393 shares worth about $40.4 million.
Insider Buying and Selling at UroGen Pharma Ltd.
On June 22, 2026, several insiders at URGN bought shares. Robinson James Jr. acquired 8,000 shares and an additional 10,000 shares. Wen Leana purchased 10,000 shares, while Belldegrun Arie bought 20,000 shares. Butitta Cynthia also acquired 10,000 shares, and Wildman Daniel George bought 10,000 shares. All these purchases were not made under Rule 10b5-1 plans.
Analysts Set New Price Targets
On May 11, 2026, HC Wainwright & Co. maintained a 'buy' rating on URGN with a price target of $45. Oppenheimer also maintained a 'buy' rating with a $40 price target on May 7, 2026. The analyst consensus remains strong with a 'buy' recommendation, supported by multiple firms.
Bottom Line
Cynthia Butitta's recent purchase of URGN shares is a notable insider transaction. Institutional investors like BlackRock have increased their stakes, indicating interest in the company. Analysts continue to support URGN with 'buy' ratings and optimistic price targets. As always, remember that insider and institutional transactions provide a snapshot of past activity and may not reflect current positions.
Related Filing Alerts
Source: Cynthia Butitta's Form 4 filing on $URGN (Jun 22, 2026). Find the original filing: URGN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts